Literature DB >> 27566795

Clinical trials of biosimilars should become more similar.

Jonathan Kay1, John D Isaacs2.   

Abstract

Entities:  

Keywords:  Anti-TNF; Disease Activity; Inflammation; Rheumatoid Arthritis; Treatment

Mesh：

Substances：

Year:  2016        PMID： 27566795     DOI： 10.1136/annrheumdis-2015-208113

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

1.  Pharmacotherapy: Biosimilar switching - "To set a form upon desired change".

Authors:  Jonathan Kay; Kevin L Winthrop
Journal:  Nat Rev Rheumatol       Date:  2017-06-01       Impact factor: 20.543

Review 2.  Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust.

Authors:  Eduardo Cazap; Ira Jacobs; Ali McBride; Robert Popovian; Karol Sikora
Journal:  Oncologist       Date:  2018-05-16

3.  [Revised version of the statement by the DGRh on biosimilars-update 2017].

Authors:  J Braun; H M Lorenz; U Müller-Ladner; M Schneider; H Schulze-Koops; Ch Specker; A Strangfeld; U Wagner; T Dörner
Journal:  Z Rheumatol       Date:  2018-02       Impact factor: 1.372

4.  Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.

Authors:  Josef S Smolen; Jung-Yoon Choe; Nenad Prodanovic; Jaroslaw Niebrzydowski; Ivan Staykov; Eva Dokoupilova; Asta Baranauskaite; Roman Yatsyshyn; Mevludin Mekic; Wieskawa Porawska; Hana Ciferska; Krystyna Jedrychowicz-Rosiak; Agnieszka Zielinska; Jasmine Choi; Young Hee Rho
Journal:  Rheumatology (Oxford)       Date:  2017-10-01       Impact factor: 7.580

Review 5.  Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.

Authors:  Morton Scheinberg; Carlos Pineda; Gilberto Castañeda-Hernández; Juan José Zarbá; Aderson Damião; Luiz H Arantes; Ira Jacobs
Journal:  MAbs       Date:  2018-08-29       Impact factor: 5.857

Review 6.  Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

Authors:  Eduardo Mysler; Valderilio Feijó Azevedo; Silvio Danese; Daniel Alvarez; Noriko Iikuni; Beverly Ingram; Markus Mueller; Laurent Peyrin-Biroulet
Journal:  Drugs       Date:  2021-10-27       Impact factor: 9.546

Review 7.  Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.

Authors:  Ross A McKinnon; Matthew Cook; Winston Liauw; Mona Marabani; Ian C Marschner; Nicolle H Packer; Johannes B Prins
Journal:  BioDrugs       Date:  2018-02       Impact factor: 5.807
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.